Introduction

Breast cancer is one of the significant reasons for cancer mortality in women.\(^1\) Accurate disease staging is a prerequisite to appropriate therapy and prediction of the prognosis for long-term survival. Locally advanced breast cancer (LABC) is defined as T0–T3 primary tumor with clinically evident ipsilateral axillary, ipsilateral infra-clavicular, supra-clavicular or internal mammary lymph nodes (IMLN) (N2–N3), or tumor involving chest wall or skin (T4) irrespective of the nodal status, corresponding to Stage III disease (T3 N1 M0, T0-T3 N2 M0, T4 N0-N2 M0, any T N3 M0). Numerous incidences of distant metastasis have been observed during the follow-up in LABC patients.\(^3\) Currently, neoadjuvant chemotherapy (NACT) along with surgery and followed by radiotherapy is the choice in such patients. Hormonal therapy is also considered a crucial element of treatment regimen in a certain subgroup of LABC patients. However, despite the extensive primary treatment, the disease recurrence within 10 years is very high (up to 35%).\(^3\) The usefulness of fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET) imaging is well reported in breast cancer for staging, re-staging, treatment monitoring, prognostication and has been found to be more accurate and valuable to other present anatomic imaging modalities (computed tomography [CT], ultrasonography, magnetic resonance imaging, and X-rays).\(^4-6\) F-18 FDG PET has also been found superior to technetium-99 m methylene di-phosphonate (Te-99 m MDP) bone scan in uncovering bony
metastasis. However, it has limitations in detecting osteoblastic malignant skeletal lesions (SL).\textsuperscript{[9,12]}

Integrin $\alpha\beta_3$ plays an essential role in angiogenesis and distant metastasis. Low expression of $\alpha\beta_3$ integrin is observed on mature endothelial and epithelial cells. However, over expression of integrin $\alpha\beta_3$ has been reported on the activated endothelial cell of the neo-vasculature of the tumor. The restriction in the expression of $\alpha\beta_3$ integrin has an important part in tumor growth and invasion. This property makes integrin $\alpha\beta_3$ a valuable molecular target to help early diagnosis and management of various solid tumors, including breast, lung, and colorectal carcinoma.\textsuperscript{[13-19]}

Various radionuclides such as Tc-99 m, F-18, Copper-64 (Cu-64), and Gallium-68 (Ga-68) have been explored for radiolabeling of arginine-glycine-aspartic acid (RGD)-based peptide ligands targeting integrin $\alpha\beta_3$. However, the preparation of Ga-68 labeled RGD has attracted considerable interest for cancer imaging because of the ease of preparation and suitable physical characteristics of the radionuclide. The labeling chemistry of Ga-68 is facile and compatible with the pharmacokinetics of many peptides.\textsuperscript{[20,21]} The peptide ligands can also be radiolabeled with therapeutic radionuclides such as lutetium-177 (Lu-177), yttrium-90 (Y-90), and actinium-225 (Ac-225) to explore their therapeutic potential. The present study was carried out to compare the angiogenesis imaging using Ga-68 labeled DOTA-RGD\textsubscript{2} with metabolic imaging using F-18 FDG in primary staging and chemotherapy response assessment in LABC patients, along with assessing the future theranostic implications of RGD in treatment-refractory cases.

**Materials and Methods**

In this prospective study, a total of 85 female patients (mean age: 50 years, age range: 28–80 years) clinically diagnosed to have LABC were included. Each patient was subjected to 2 whole-body PET/CT scans (with Ga-68-DOTA-RGD\textsubscript{2} and F-18 FDG) before the start (in 85 patients) and after the completion (in 30 patients) of NACT. Both the studies were performed on two different days, within 1 week of each other, in random order. The Institutional Ethics Committee duly approved the study before recruiting patients (Approval no. Histopath/13/NK/2421, dated 08.12.2013). Written informed consent was obtained from each participant before enrolment.

At least 6 h of fasting and blood glucose level <200 mg/dL was ensured for the F-18 FDG study. Hybrid PET/CT images were acquired approximately 45 min after intravenous administration of F-18 FDG at a dose of 5 MBq/Kg body weight, using dedicated PET/CT scanners [Discovery 710 or Discovery STE-16, GE Healthcare, Milwaukee, USA]. Both oral and intravenous contrast agents were given in all F-18 FDG studies. Diagnostic CT images were acquired first, followed by PET images in 6–7 bed positions (90 s per bed).

For Ga-68-DOTA-RGD\textsubscript{2} PET/CT, no special patient preparation was required. Images were acquired 40–45 min after slow intravenous injection of the radiotracer (2 MBq/Kg body weight). The image acquisition protocol used was similar to that of the F-18 FDG study. However, noncontrast low dose CT was performed instead, followed by PET images (6–7 bed positions) with each bed position for 120 s. Both the scans were acquired on the same PET/CT machine.

**Data analysis**

Data obtained from both the scans postattenuation correction were reconstructed using iterative reconstruction and ordered subset expectation maximization algorithm. The reconstructed images were displayed in transaxial, sagittal, and coronal views for qualitative and semi-quantitative evaluation. Two certified nuclear medicine physicians evaluated all the scans independently. Both the reviewers were blinded to the participant’s clinical history and other parameters. For semi-quantitative assessment, standardized uptake value (SUV) estimation was done for uptake of Ga-68-DOTA-RGD\textsubscript{2} and F-18 FDG by drawing a circular region of interest over the entire lesion. It was expressed as SUV\textsubscript{max} (RGD) and SUV\textsubscript{max} (FDG), respectively. The areas with increased focal uptake in the skeleton were considered malignant unless a benign cause, for example, degenerative bone disease was localized on corresponding CT images.

Response assessment was done as per RECIST 1.1 criteria. Complete disappearance, i.e., 100% decrease of the target lesion is considered as complete response (CR), 30% shrinkage in the longest diameter of the target lesion, as partial response (PR), 20% growth in the longest diameter of the target lesion as progressive disease (PD), and stable disease (SD)—neither PR nor PD. The response to chemotherapy (ΔSUV %) after eight cycles of chemotherapy was calculated as follows:

$$\Delta\text{SUV} (%) = 100 \times (\text{Baseline SUV max} – \text{Posttherapy SUV max})/\text{Baseline SUV max}$$

**Histopathological assessment**

Biopsy samples from patients were subjected to immunohistochemistry (IHC). Micro-vessel density (MVD) was calculated to assess the level of neo-angiogenesis and to see any correlation with SUV values of Ga-68-DOTA-RGD\textsubscript{2} and F-18 FDG.

**Immunohistochemistry**

IHC for endothelial cells was done using anti-CD31 antibody (Abcam, 1:50 dilution). Briefly, the sections of 4–5 μm thickness were mounted on 0.01% poly-L-lysine coated slides. Xylene dewaxed sections were rehydrated in a series of graded alcohol and then washed in phosphate buffered saline.
buffer saline. The endogenous peroxidase activity was blocked with freshly prepared 0.03% hydrogen peroxide in methanol for 20 min. Antigen was recovered employing the heat retrieval method using PT link in citrate buffer (pH 5.9). Primary antibody was used on the sections for 1 h, followed by incubation with secondary antibody (Dako Envision) for 40 min. A coloured reaction was developed by Di-amine benzidine and counterstaining was done by using hematoxylin. The sections were then dehydrated and mounted with Dextrene Phthalate Xylene.

**Micro-vessel density calculation**

For microscope independent MVD values, counts were expressed as the number of microvessels/mm² (1 HPF = 0.17 mm²). Density counts of micro-vessels stained with CD31 were executed. Two independent investigators identified vascular “hot spots” at low power, and stained vessels were counted at x40 in at least five independent microscopic fields of each tissue section. MVD count was obtained by dividing the mean of five fields by the field area. For the proper delineation of tumor vasculature, vessel counting was avoided in the peripheral regions and was carried out at the center of the tumor.

**Statistical analysis**

Statistical analysis was carried out using a statistical package for social sciences (SPSS Inc., IBM, Chicago, Illinois, United States, version 23.0 for windows) software. The demographic profile of all participants was expressed in the form of descriptive statistics such as mean, standard deviation, and range. Both diagnostic methods were compared to each other for the number of skeletal, liver, or nodal metastasis, or metastasis to other sites (OS) both before (in 85 patients) and after completion (in 30 patients) of chemotherapy. For response prediction, the threshold SUV change was calculated by using receiver-operating characteristic (ROC) analysis. Correlation between the paired variables was done using Spearman’s Rho. 

**Results**

**Baseline study**

Both Ga-68-DOTA-RGD₂ and F-18 FDG show good uptake at the primary tumor site in all 85 patients with mean \(\text{SUV}_{\text{max}}\) \(_{\text{RGD}}\) 6.7 ± 3.1 (range 2.5–20.7) and mean \(\text{SUV}_{\text{max}}\) \(_{\text{FDG}}\) 13.1 ± 5.9 (range 3.4–32.0). Regional lymph nodes (ipsilateral axillary lymph nodes and ipsilateral IMLN) were Ga-68-DOTA-RGD₂ avid in 77 (90.5%) and 22 (25.8%) patients and F-18 FDG avid in 80 (94.1%) and 27 (31.7%) patients. Contralateral axillary lymph nodes (CALN) were found in 10 (11.7%) versus 11 (12.9%) patients on Ga-68-DOTA-RGD₂ versus F-18 FDG study, respectively. Ipsilateral supra-clavicular lymph nodes (ISCL) were seen in 17 (20%) versus 21 (24.7%) patients on Ga-68-DOTA-RGD₂ versus F-18 FDG scans, respectively, as shown in Figure 1. A total of 10 patients with hypo-attenuating liver lesions (LLs) on CT images showed F-18 FDG uptake, but none revealed avidity for RGD. Lytic SLs were Ga-68-DOTA-RGD₂ avid in 23 (27.0%) patients and F-18 FDG avid in 24 (28.2%) patients [Figure 2]. Lesions at OS, i.e., brain, contralateral breast, and adrenal lesions, lung nodules, pleural deposits, mediastinal, and abdominal lymph nodes were detected in 11 versus 16 patients on Ga-68-DOTA-RGD₂ and F-18 FDG study, respectively.

The direct comparison of PET/CT findings using these two tracers reveals that both could identify contralateral breast lesions (two patients; with supra-clavicular lymph nodes in one patient), lung nodules (six patients), mediastinal and abdominal lymph nodes (in 2 and 3 patients, respectively), and brain lesion (1 patient). However, lymph nodes in mediastinum, lung nodules, and adrenal lesion each in one patient were F-18 FDG avid, whereas Ga-68-DOTA-RGD₂ did not show any uptake in these lesions. M stage was changed from Mx to M1 in 31 (36.5%) patients on Ga-68-DOTA-RGD₂ and 38 (44.7%) on F-18 FDG studies.

The lesion wise analysis of both radiotracers is shown in Table 1. A total of 1156 lesions were identified on F-18 fluorodeoxyglucose positron emission tomography/computed tomography and Ga-68-DOTA-RGD₂. Most lesions were F-18 FDG avid in 11 versus 16 patients on Ga-68-DOTA-RGD₂ and F-18 FDG study, respectively.

**Micro-vessel density correlation**

MVD was calculated in 62 patients with anti-CD31 IHC in core biopsy samples from the primary tumor [Figure 3]. Mean MVD count was 110.1 ± 35.3. No statistically significant correlation of MVD was seen either with \(\text{SUV}_{\text{max}}\) \(_{\text{RGD}}\) or \(\text{SUV}_{\text{max}}\) \(_{\text{FDG}}\). Spearman’s correlation coefficient values were 0.08 for \(\text{SUV}_{\text{max}}\) \(_{\text{RGD}}\) and 0.088 for \(\text{SUV}_{\text{max}}\) \(_{\text{FDG}}\), respectively [Table 2].
Postchemotherapy study

A total of 30 patients have undergone both Ga-68-DOTA-RGD₂ and F-18 FDG PET/CT imaging in LABC. In 10 patients, complete resolution of the primary tumor was seen, and in the rest of 20 patients, both the tracers showed a decrease in the uptake with mean $SUV_{\text{max}}^{(\text{RGD})}$ $3.42 \pm 0.74$ and mean $SUV_{\text{max}}^{(\text{FDG})}$ $3.2 \pm 0.59$, respectively, suggesting residual primary tumor [Figure 4]. In the posttherapy scans, nine of these 30 patients showed Ga-68-DOTA-RGD₂ and F-18 FDG avid residual ipsilateral axillary lymph nodes. SL (7/30 patients), ipsilateral internal mammary (3/30 patients), ISCL (2/30 patients) also showed radiotracer uptake in both the scans. One patient with LL and another with pleural lesions showed F-18 FDG uptake but no Ga-68-DOTA-RGD₂ uptake in the posttherapy scans. No lymph nodes in the contralateral axilla were detected in any patient on both scans. Lung nodules were noted in one patient on both scans.

Table 1: Lesion-wise analysis of Ga-68-DOTA-RGD₂ and F-18 fluorodeoxyglucose

| Lesion                        | RGD positive | FDG positive | Concordant | Discordant |
|-------------------------------|--------------|--------------|------------|------------|
| Primary (including satellite nodules) | 145          | 145          | 145        | 0          |
| IALN                          | 443          | 447          | 443        | 4          |
| CALN                          | 39           | 40           | 39         | 1          |
| IMLN                          | 45           | 54           | 45         | 9          |
| ISCL                          | 55           | 65           | 55         | 10         |
| LL                            | 0            | 44           | 0          | 44         |
| SL                            | 266          | 267          | 266        | 1          |
| Contralateral breast lesion    | 2            | 2            | 2          | 0          |
| Lung nodules                  | 40           | 42           | 40         | 2          |
| Mediastinal lymph nodes        | 21           | 30           | 21         | 9          |
| Pleural deposits               | 0            | 5            | 0          | 5          |
| Abdominal lymph nodes          | 13           | 13           | 13         | 0          |
| Brain lesion                   | 1            | 1            | 1          | 0          |
| Adrenal lesion                 | 0            | 1            | 0          | 1          |
| Total number of lesions        | 1070         | 1156         | 1070       | 86         |

IALN: Ipsilateral axillary lymph node, IMLN: Ipsilateral internal mammary, CALN: Contralateral axillary lymph node, ISCL: Ipsilateral supra-clavicular lymph, LL: Liver lesion, SL: Skeletal lesion, RGD: Ga-68-DOTA-RGD₂

Figure 2: A 65-year-old female with locally advanced breast cancer referred for initial evaluation: (a) MIP image of F-18 fluorodeoxyglucose positron emission tomography/computed tomography, (b) fused transaxial F-18 fluorodeoxyglucose positron emission tomography/computed tomography sections, (c) computed tomography sections and (d) transaxial fused Ga-68-DOTA-RGD₂ positron emission tomography/computed tomography images (e) MIP image of Ga-68-DOTA-RGD₂ positron emission tomography/computed tomography. In the top row, F-18 fluorodeoxyglucose and Ga-68-DOTA-RGD₂ uptake is noted in primary tumor in the right breast. In middle row uptake of both tracers is seen in ipsilateral and contralateral axillary lymph nodes. Bottom row showing uptake of both tracers in lytic lesion in the right iliac bone.

Figure 3: Microphotographs showing micro-vessels highlighted by CD31 immunostain (a) ×10 image (b) ×40 image.
Response assessment

The response to chemotherapy was evaluated by RECIST 1.1 criteria. Twenty-seven patients showed favorable response to chemotherapy. CR was noted in 10 of these 27 patients and PR in 17 patients. In nonresponder category, two patients had stable SD while one showed PD.

Determination of Δ standardized uptake value (%) threshold

For differentiation of responders (CR or PR) and nonresponders (SD or PD) after completion of chemotherapy, ROC analysis indicated Δ SUV(%) threshold of 35% (sensitivity of 80% and specificity of 75%) for Ga-68-DOTA-RGD₂ and 45% (sensitivity of 92% and specificity of 75%) for F-18 FDG [Figure 5]. Based on these cutoffs, seven patients were labeled as nonresponders on Ga-68-DOTA-RGD₂ and five on F-18 FDG [Table 3]. In nonresponder group, three patients had concordance with RECIST 1.1 criteria and both Ga-68-DOTA-RGD₂ and F-18 FDG scan findings while two patients on F-18 FDG and four patients on Ga-68-DOTA-RGD₂ had discordant results. In responder group, in comparison to RECIST 1.1 criteria, 23 and 25 patients had concordance with Ga-68-DOTA-RGD₂ and F-18 FDG scans, respectively. However, discordant results were observed in four patients on Ga-68-DOTA-RGD₂ and in two patients on F-18 FDG scan.

Table 2: Correlation of micro-vessel density with maximum standardized uptake value of RGD and FDG

| MVD | SUVmax (RGD) | SUVmax (FDG) |
|-----|--------------|--------------|
| Spearman’s rho coefficient | -0.080 | 0.088 |
| *P ≤0.05 is significant. MVD: Micro-vessel density, SUVmax: Maximum standardized uptake value, RGD: Ga-68-DOTA-RGD₂ |

Table 3: Response assessment, comparison between RECIST 1.1 and positron emission tomography

| PET criteria | RGD | FDG |
|--------------|-----|-----|
| Responders (CR/PR) | 27 (10/17) | 23 (10/13) |
| Non responders (SD/PD) | 3 (2/1) | 7 (6/1) |

Response assessment based on ΔSUV (%) cut-off of 45% and 35% for FDG and RGD respectively. CR: Complete response, PR: Partial response, SD: Stable disease, PD: Progressive disease, FDG: Fluorodeoxyglucose, PET: Positron emission tomography, RGD: Ga-68-DOTA-RGD₂

![Figure 4](image-url) Figure 4: Patient in Figure 2 after eight cycles of chemotherapy: (a) MIP image of F-18 FDG PET/CT, (b) fused transaxial F-18 fluorodeoxyglucose positron emission tomography/computed tomography sections, (c) computed tomography sections (d) transaxial fused Ga-68-DOTA-RGD₂ PET/CT images and (e) MIP image of Ga-68-DOTA-RGD₂. In top row F-18 FDG and Ga-68-DOTA-RGD₂ uptake is noted in residual primary tumor in right breast. Bottom row showing lytic-sclerotic lesion, with no uptake of either F-18 fluorodeoxyglucose or Ga-68-DOTA-RGD₂

![Figure 5](image-url) Figure 5: (a) ROC analysis curve, establishing optimal cutoff values of ΔSUV (%) for F-18 FDG, (b) ROC analysis curve, establishing optimal cutoff values of ΔSUV (%) for Ga-68-DOTA-RGD₂
Discussion

The diagnosis at the early stage of the disease in breast cancer makes cure possible. Imaging modalities that could detect disease early and identify regional and distant disease spread help plan the management.[23]

F-18 FDG PET is a highly sensitive modality for illustrating lymph nodal disease (sub-and inter-pectoral disease, supra-and intra-clavicular and internal mammary chain) and other metastatic lesions in breast cancer. However, it lacks specificity due to its uptake in infectious/inflammatory conditions and reactive lymph nodal hyperplasia, which must be confirmed histologically.[24] In the present study, both Ga-68-DOTA-RGD$_2$ and F-18 FDG studies were equally sensitive for the detection of primary tumor; however, F-18 FDG was observed to be more sensitive in the evaluation of disease spread to regional lymph nodes.

Distant metastasis in a patient precludes the radical surgery and needs to be managed with palliative chemotherapy or radiotherapy. Both radiotracers Ga-68-DOTA-RGD$_2$ and F-18 FDG are useful to uncover distant metastases. In our study, comprising clinically suspected LABC patients, 31/85 patients (36.5%) on Ga-68-DOTA-RGD$_2$ and 38/85 (44.7%) patients on F-18 FDG scans, were upstaged from M0 to M1. Skeletal metastasis (osteolytic lesions) was seen in 23 versus 24 patients on Ga-68-DOTA-RGD$_2$ versus F-18 FDG study. However, RGD expression was not seen in any metastatic LLs [Figure 6]. Similar observations showing the inability of RGD peptides to detect hepatocellular carcinoma and metastatic LLs have been reported earlier. However, the exact reason was not ruled out.[25,26] OS of metastasis were CALN, contralateral breast lesions, lung nodules, pleural soft-tissue deposits, mediastinal and abdominal lymphadenopathy, adrenal gland and brain lesions. All these lesions were detected by F-18 FDG study, but Ga-68-DOTA-RGD$_2$ did not show any uptake in pleural soft-tissue deposits, lung nodule and mediastinal lymph nodes (each in 1 patient). This needs further investigation in future studies with larger patient population.

Another focus of this study was response assessment to NACT. In the responder group, concordance was noted between RECIST 1.1 and $\Delta$ SUV (%) threshold values of F-18 FDG in 25 patients and Ga-68-DOTA-RGD$_2$ in 23 patients. In both the studies, CR was observed in total of 10 patients. In the nonresponder group, good agreement between RECIST 1.1 and $\Delta$ SUV (%) threshold values (of both tracers) was observed in 3 patients.

High expression of integrin $\alpha_v\beta_3$ has been reported on activated endothelial cells and tumor cells. The role of $\alpha_v\beta_3$ integrin in regulating tumor growth and distant metastasis is well known. Previous preclinical and clinical studies have demonstrated the correlation between $\alpha_v\beta_3$ expression in tumor and uptake of radiolabeled RGD peptides.[27,28] Expression of $\alpha_v\beta_3$ could not be evaluated in this study due to some technical reasons; however, the MVD was evaluated by CD31 expression to demonstrate neo-angiogenesis in pretherapy biopsy samples. MVD results did not correlate with either $\text{SUV}_{\text{max}}$ (RGD) or $\text{SUV}_{\text{max}}$ (FDG) values in this study. The possible reason could be that the core biopsy samples were not guided by Ga-68-DOTA-RGD$_2$ or F-18 FDG uptake in the primary tumor.

The synthesis of Ga-68-DOTA-RGD$_2$ is facile providing good yield. Moreover, patients who are nonresponsive to neo-adjuvant chemotherapy and have advanced disease may in future be candidates for radionuclide therapy using $^{177}$Lu-$^{90}$Y-RGD.

Conclusion

F-18 FDG appears better tracer for primary staging and chemotherapy response assessment than Ga-68-DOTA-RGD$_2$ in LABC patients. Further RGD peptide also missed metastatic LL, pleural deposits, and adrenal lesion.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Perez EA, Foo ML, Fulmer JT. Management of locally advanced breast cancer. Oncology (Williston Park) 1997;11:9-17.
3. van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000;92:1143-50.

4. Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol 2000;18:3495-502.

5. Mittal BR, Manohar K, Kashyap R, Bhattacharya A, Singh B, Singh G. The role of 18F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging. Hell J Nucl Med 2011;14:135-9.

6. Suárez M, Pérez-Castejón MJ, Jiménez A, Domper M, Ruiz G, Montz R, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 2002;46:113-21.

7. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006;33:254-62.

8. Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, et al. Performance of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 2005;7:369-76.

9. Huyge V, Garcia C, Vanderstappen A, Alexiou J, Gil T, Flam P. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET. Clin Nucl Med 2009;34:417-20.

10. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32:1253-8.

11. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18F-FDG PET. Clin Nucl Med 2007;32:1253-8.

12. Cook GJ, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med 2001;31:50-61.

13. Clezardin P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci 1998;54:541-8.

14. Eliceiri BP, Cherehs DA. The role of alpha integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest 1999;103:1227-30.

15. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of the integrins. Med Res Rev 1994;14:195-228.

16. Brooks PC, Strømblad S, Klemke R, Visscher D, Sarkar FH, Cherehs DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-22.

17. Takayama S, Ishii S, Ikeda T, Masamura S, Doi M, Kitajima M. The relationship between bone metastasis from human breast cancer and integrin alpha(v) beta3 expression. Anticancer Res 2005;25:79-83.

18. Fugger KA, Allan AL, Wilson SM, Hota C, Vantyghem SA, Postenka CO, et al. Beta (3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 2003;1:810-9.

19. Vellon L, Menendez JA, Liu H, Lupu R. Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner. Differentiation 2007;75:819-30.

20. Dijkgraaf I, Yim CB, Franssen GM, Schuit RC, Luurtsema G, Liu S, et al. PET imaging of ovβ3 integrin expression in tumours with 68Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging 2011;38:128-37.

21. Vatsa R, Ashwathananayga AG, Shukla J, Singh S, Bhusari P, Kumar R, et al. Multifarious Ga-68 labeled PET radiopharmaceuticals in imaging various malignancies. Indian J Nucl Med 2018;33:242-4.

22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.

23. Kumar R, Alavi A. Fluorodeoxyglucose-PET in the management of breast cancer. Radiol Clin North Am 2004;42:1113-22.

24. Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E, et al. Effect of 18F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008;71:695-704.

25. Haubner R, Finkenstedt A, Stegmayer A, Rangger C, Decristoforo C, Zoller H, et al. [68Ga]NODAGA-RGD- Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. Eur J Nucl Med Mol Imaging 2016;43:2005-13.

26. Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Bhusari P, Kumar R, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008;49:879-86.

27. Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Naehr J, Watzlowski P, et al. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008;49:255-9.

28. Vatsa R, Shukla J, Kumar S, Chakraboarty S, Dash A, Singh G, et al. Effect of macro-cyclic bifunctional chelators DOTA and NODAGA on radiolabeling and in vivo biodistribution of Ga-68 cyclic RGD dimer. Cancer Biother Radiopharm 2019;34:427-35.